transforming-growth-factor-alpha has been researched along with Tuberculosis--Pulmonary* in 3 studies
1 trial(s) available for transforming-growth-factor-alpha and Tuberculosis--Pulmonary
Article | Year |
---|---|
Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report.
Interferon gamma release assays, including the QuantiFERON TB Gold In Tube (QFT) have been shown to be accurate in diagnosing Mycobacterium tuberculosis infection. These assays however, do not discriminate between latent TB infection (LTBI) and active TB disease.. We recruited twenty-three pulmonary TB patients and 34 household contacts from Cape Town, South Africa and performed the QFT test. To investigate the ability of new host markers to differentiate between LTBI and active TB, levels of 29 biomarkers in QFT supernatants were evaluated using a Luminex multiplex cytokine assay.. Eight out of 29 biomarkers distinguished active TB from LTBI in a pilot study. Baseline levels of epidermal growth factor (EGF) soluble CD40 ligand (sCD40L), antigen stimulated levels of EGF, and the background corrected antigen stimulated levels of EGF and macrophage inflammatory protein (MIP)-1beta were the most informative single markers for differentiation between TB disease and LTBI, with AUCs of 0.88, 0.84, 0.87, 0.90 and 0.79 respectively. The combination of EGF and MIP-1beta predicted 96% of active TB cases and 92% of LTBIs. Combinations between EGF, sCD40L, VEGF, TGF-alpha and IL-1alpha also showed potential to differentiate between TB infection states. EGF, VEGF, TGF-alpha and sCD40L levels were higher in TB patients.. These preliminary data suggest that active TB may be accurately differentiated from LTBI utilizing adaptations of the commercial QFT test that includes measurement of EGF, sCD40L, MIP-1beta, VEGF, TGF-alpha or IL-1alpha in supernatants from QFT assays. This approach holds promise for development as a rapid diagnostic test for active TB. Topics: Adult; Biomarkers; CD40 Ligand; Contact Tracing; Epidermal Growth Factor; Female; Humans; Incidence; Interferon-gamma; Interleukin-1alpha; Male; Microbiological Techniques; Middle Aged; Pilot Projects; Reagent Kits, Diagnostic; South Africa; Transforming Growth Factor alpha; Tuberculosis, Pulmonary; Vascular Endothelial Growth Factor A | 2009 |
2 other study(ies) available for transforming-growth-factor-alpha and Tuberculosis--Pulmonary
Article | Year |
---|---|
Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis.
We investigated host-derived biomarkers that were previously identified in QuantiFERON supernatants, in a large pan-African study. We recruited individuals presenting with symptoms of pulmonary TB at seven peripheral healthcare facilities in six African countries, prior to assessment for TB disease. We then evaluated the concentrations of 12 biomarkers in stored QuantiFERON supernatants using the Luminex platform. Based on laboratory, clinical and radiological findings and a pre-established algorithm, participants were classified as TB disease or other respiratory diseases(ORD). Of the 514 individuals included in the study, 179(34.8%) had TB disease, 274(51.5%) had ORD and 61(11.5%) had an uncertain diagnosis. A biosignature comprising unstimulated IFN-γ, MIP-1β, TGF-α and antigen-specific levels of TGF-α and VEGF, identified on a training sample set (n = 311), validated by diagnosing TB disease in the test set (n = 134) with an AUC of 0.81(95% CI, 0.76-0.86), corresponding to a sensitivity of 64.2%(95% CI, 49.7-76.5%) and specificity of 82.7%(95% CI, 72.4-89.9%). Host biomarkers detected in QuantiFERON supernatants can contribute to the diagnosis of active TB disease amongst people presenting with symptoms requiring investigation for TB disease, regardless of HIV status or ethnicity in Africa. Topics: Adult; Africa; Biomarkers; Chemokine CCL4; Cytokines; Female; HIV Infections; Humans; Interferon-gamma; Male; Mass Screening; Middle Aged; Sensitivity and Specificity; Transforming Growth Factor alpha; Tuberculosis, Pulmonary; Vascular Endothelial Growth Factor A | 2018 |
Microdissection of the cytokine milieu of pulmonary granulomas from tuberculous guinea pigs.
Levels of IL-12p40, TNFalpha, TGFbeta, IFNgamma and IL-10 mRNA were assessed by laser capture microdissection followed by quantitative real-time PCR in the pulmonary granulomas of unimmunized and BCG-vaccinated guinea pigs infected by aerosol with virulent Mycobacterium tuberculosis. Lesions microdissected from unimmunized guinea pigs were overwhelmed by the pro-inflammatory TNFalpha mRNA at both 3 and 6 weeks post infection, indicating the struggle to control the mounting infection. The cytokine profile of granulomas from vaccinated guinea pigs shifted from type 1 cytokine mRNA (IFNgamma and IL-12p40) at 3 weeks to a predominantly anti-inflammatory environment (TGFbeta mRNA) at 6 weeks. The relative proportions of cytokine mRNA transcripts in the periphery of the granuloma were different from the centre, reflecting differences in cell composition and architecture. Moreover, analysis of the individual lung lobes at 6 weeks post infection suggests that heterogeneity exists in the cytokine profile between the lobes of the lung. Topics: Animals; BCG Vaccine; Cytokines; Gene Expression Profiling; Granuloma; Guinea Pigs; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-12 Subunit p40; Lung; Microdissection; Mycobacterium tuberculosis; RNA, Messenger; Time Factors; Transforming Growth Factor alpha; Transforming Growth Factor beta; Tuberculosis, Pulmonary; Virulence | 2007 |